-
CLK2, BRCA1, and Platinum Resistance in Ovarian Cancer
2026-08-26
The reference study identifies Cdc2-like kinase 2 (CLK2) as a contributor to platinum resistance in ovarian cancer and connects its activity to BRCA1 Ser1423 phosphorylation and DNA damage repair. Its tissue, cellular, mechanistic, and xenograft evidence supports CLK2 as a candidate resistance pathway while also highlighting the need for selective, clinically validated interventions.
-
MLKL Polymerization, Lysosomal Leakage, and Necroptosis
2026-08-26
The reference study identifies lysosomal membrane permeabilization as a critical intermediate between MLKL polymerization and necroptotic plasma membrane rupture. Its experiments place cathepsin B downstream of lysosomal disruption and show that pharmacological inhibition or genetic depletion of cathepsin B can protect cells from necroptosis.
-
SIRT1/2 Inhibitor IV (cambinol) Workflows
2026-08-25
This scenario-based guide explains how SIRT1/2 Inhibitor IV (cambinol), SKU B6063, can be incorporated into viability, proliferation, apoptosis, CNS injury, and tumor research workflows. It emphasizes concentration interpretation, DMSO and storage controls, orthogonal readouts, and vendor-selection criteria grounded in the available biochemical and in vivo data.
-
BV6 and Cell-Death Assay Design in Cancer Research
2026-08-25
BV6 is an IAP antagonist that helps researchers investigate apoptosis, therapeutic sensitization, and cell-death pathway dependence. This article develops an assay-design framework that distinguishes IAP-mediated apoptotic priming from RIPK3–MLKL necroptosis competence.
-
Polygodial in TRPA1 and Cell Assays
2026-08-24
Learn how Polygodial, SKU B7311, can support controlled TRPA1 activation studies while helping researchers distinguish ion-channel signaling from nonspecific effects in viability and cytotoxicity assays. This scenario-based guide covers assay compatibility, handling, protocol design, interpretation, and practical vendor selection.
-
α-Bungarotoxin: Blocking Signaling to Prove Mechanism
2026-08-24
α-Bungarotoxin turns cholinergic pathway observation into a testable causal model. This thought-leadership guide shows how selective α7 nAChR antagonism can strengthen neuroscience, neurotoxicity, and placental translational research while clarifying experimental limits.
-
ARCA EGFP mRNA (5-moUTP): Contextual Assays
2026-08-23
ARCA EGFP mRNA (5-moUTP) can serve as more than a fluorescence reporter: it is a practical instrument for separating cargo performance from delivery-context effects. This article connects polyadenylated mRNA design with LNP structure, administration route, and inflammatory biology to improve assay interpretation.
-
Solanesol (B8776): Practical Assay Guide
2026-08-22
Solanesol (SKU B8776) provides a defined polyisoprenoid alcohol for hydrophobic biochemical, membrane-related, cell-based, and enzyme workflow development. Its insolubility in water and ethanol requires DMSO-based preparation, fresh-solution handling, solvent-matched controls, and clear separation between research use and clinical or diagnostic applications.
-
CD36-Driven Lipid Signaling Promotes Immune Escape in AML
2026-08-21
Guo et al. identify a non-canonical CD36-dependent lipid-sensing pathway in acute myeloid leukemia that suppresses T-cell activity independently of lipid oxidation. Their findings connect oxidized LDL and palmitate uptake with resistance to decitabine and show that lipid-lowering statins can improve hypomethylating-agent efficacy in experimental AML models.
-
Ibotenic Acid: From Excitotoxicity to Translation
2026-08-20
A translational framework for using Ibotenic acid as an NMDA receptor agonist: connecting glutamatergic mechanism, time-resolved toxicology, model selection, product qualification, and circuit-level neuroscience research.
-
DOTAP and the Next Wave of Immune-Metabolic Delivery
2026-08-20
A translational perspective on how 1,2-Dioleoyl-3-trimethylammonium-propane chloride can connect nucleic acid delivery, functional genomics, and immune-metabolic research—while keeping formulation hypotheses distinct from validated evidence.
-
SM-102: From LNP Mechanism to Translational Strategy
2026-08-19
A translational perspective on SM-102, connecting ionizable-lipid function, mRNA delivery, formulation controls, and localized oncology applications while distinguishing platform evidence from product-specific validation.
-
LY2109761 Workflows for TGF-β Signaling
2026-08-19
LY2109761 provides a practical way to interrogate receptor-proximal TGF-β signaling in cancer, fibrosis, and radiation-response models. This guide connects Smad2/3 phosphoprotein assays with functional workflows, reference-study insights, and troubleshooting strategies for more reproducible pathway experiments.
-
Aneugen Molecular Mechanism Assay: 27-Chemical Study
2026-08-18
Bernacki and colleagues developed a tiered flow-cytometric strategy that distinguishes tubulin stabilization, tubulin destabilization, and mitotic kinase inhibition among aneugenic chemicals. Its combination of biomarker profiling, Taxol-associated fluorescence, and machine learning improved mechanistic interpretation beyond a simple positive or negative genotoxicity result.
-
Sulfo-Cy5 in Translational Mucosal Research
2026-08-18
How Sulfo-Cy5 carboxylic acid can help translational researchers connect nanoparticle distribution, intestinal targeting, and immune-function readouts without confusing fluorescent tracking with biological efficacy.